Emerging CRISPR/Cas9 applications for T-cell gene editing

Published on May 31, 2019
· DOI :10.1042/ETLS20180144
Roland Preece2
Estimated H-index: 2
C Georgiadis4
Estimated H-index: 4
Gene editing tools are being rapidly developed, accelerating many areas of cell and gene therapy research. Each successive gene editing technology promises increased efficacy, improved specificity, reduced manufacturing cost and design complexity; all of which are currently epitomised by the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein (Cas9) platform. Since its conceptualisation, CRISPR-based gene editing has been applied to existing methodologies and has further allowed the exploration of novel avenues of research. Implementation of CRISPR/Cas9 has been instrumental to recent progress in the treatment of cancer, primary immunodeficiency, and infectious diseases. To this end, T-cell therapies have attempted to harness and redirect antigen recognition function, and through gene editing, broaden T-cell targeting capabilities and enhance their potency. The purpose of this review is to provide insights into emerging applications of CRISPR/Cas9 in T-cell therapies, to briefly address concerns surrounding CRISPR-mediated indel formation, and to introduce CRISPR/Cas9 base editing technologies that hold vast potential for future research and clinical translation.
  • References (158)
  • Citations (1)
📖 Papers frequently viewed together
6 Authors (Xueli Tian, ..., Zigang Dong)
2 Citations
23 Citations
9 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Wanghong Hu (SJTU: Shanghai Jiao Tong University)H-Index: 1
#2Zhenguo Zi (SJTU: Shanghai Jiao Tong University)H-Index: 1
Last. Fang Wei (SJTU: Shanghai Jiao Tong University)H-Index: 8
view all 8 authors...
The interaction between programmed cell death protein 1 (PD-1) on activated T cells and its ligands on a target tumour may limit the capacity of chimeric antigen receptor (CAR) T cells to eradicate solid tumours. PD-1 blockade could potentially enhance CAR T cell function. Here, we show that mesothelin is overexpressed in human triple-negative breast cancer cells and can be targeted by CAR T cells. To overcome the suppressive effect of PD-1 on CAR T cells, we utilized CRISPR/Cas9 ribonucleoprote...
8 CitationsSource
#1Vasyl Eisenberg (BIU: Bar-Ilan University)H-Index: 2
#2Shiran Hoogi (BIU: Bar-Ilan University)H-Index: 2
Last. Cyrille J. Cohen (BIU: Bar-Ilan University)H-Index: 23
view all 5 authors...
Abstract The last decade will be remembered as the dawn of the immunotherapy era during which we have witnessed the approval by regulatory agencies of genetically engineered CAR T-cells and of checkpoint inhibitors for cancer treatment. Understandably, T-lymphocytes represent the essential player in these approaches. These cells can mediate impressive tumor regression in terminally-ill cancer patients. Moreover, they are amenable to genetic engineering to improve their function and specificity. ...
2 CitationsSource
#1Carsten T. Charlesworth (Stanford University)H-Index: 3
#2Deshpande Ps (Stanford University)H-Index: 1
Last. Matthew H. Porteus (Stanford University)H-Index: 46
view all 20 authors...
The CRISPR–Cas9 system is a powerful tool for genome editing, which allows the precise modification of specific DNA sequences. Many efforts are underway to use the CRISPR–Cas9 system to therapeutically correct human genetic diseases1–6. The most widely used orthologs of Cas9 are derived from Staphylococcus aureus and Streptococcus pyogenes5,7. Given that these two bacterial species infect the human population at high frequencies8,9, we hypothesized that humans may harbor preexisting adaptive imm...
63 CitationsSource
#1Lee A. Campbell (NIDA: National Institute on Drug Abuse)H-Index: 2
#2Lamarque M. Coke (NIDA: National Institute on Drug Abuse)H-Index: 3
Last. Brandon K. Harvey (NIDA: National Institute on Drug Abuse)H-Index: 35
view all 6 authors...
Investigators have utilized the CRISPR/Cas9 gene-editing system to specifically target well-conserved regions of HIV, leading to decreased infectivity and pathogenesis in vitro and ex vivo . We utilized a specialized extracellular vesicle termed a “gesicle” to efficiently, yet transiently, deliver Cas9 in a ribonucleoprotein form targeting the HIV long terminal repeat (LTR). Gesicles are produced through expression of vesicular stomatitis virus glycoprotein and package protein as their cargo, th...
5 CitationsSource
#1Diogo Gomes-Silva (IST: Instituto Superior Técnico)H-Index: 4
#2Erden Atilla (Center for Cell and Gene Therapy)H-Index: 1
Last. Maksim Mamonkin (BCM: Baylor College of Medicine)H-Index: 10
view all 12 authors...
Chimeric antigen receptor (CAR) T cell therapy for the treatment of acute myeloid leukemia (AML) has the risk of toxicity to normal myeloid cells. CD7 is expressed by the leukemic blasts and malignant progenitor cells of approximately 30% of AML patients but is absent on normal myeloid and erythroid cells. Since CD7 expression by malignant blasts is also linked with chemoresistance and poor outcomes, targeting this antigen may be beneficial for this subset of AML patients. Here, we show that exp...
6 CitationsSource
#1Beau R. WebberH-Index: 10
#2Cara-lin Lonetree (UMN: University of Minnesota)H-Index: 2
Last. Branden S. Moriarity (UMN: University of Minnesota)H-Index: 17
view all 14 authors...
Chimeric antigen receptor engineered T cell (CAR-T) immunotherapy has shown efficacy against a subset of hematological malignancies, yet its autologous nature and ineffectiveness against epithelial and solid cancers limit widespread application. To overcome these limitations, targeted nucleases have been used to disrupt checkpoint inhibitors and genes involved in alloreactivity. However, the production of allogeneic, off-the-shelf T cells with enhanced function requires multiplex genome editing ...
1 CitationsSource
#1Hui YangH-Index: 19
#2LIYixueH-Index: 57
Last. Lars M. Steinmetz (Stanford University)H-Index: 56
view all 8 authors...
Genome editing tools including CRISPR/Cas9 and base editors hold great promise for correcting pathogenic mutations. Unbiased genome-wide off-target effects of the editing in mammalian cells is required before clinical applications, but determination of the extent of off-target effects has been difficult due to the existence of single nucleotide polymorphisms (SNPs) in individuals. Here, we developed a method named GOTI (Genome-wide Off-target analysis by Two-cell embryo Injection) to detect off-...
4 CitationsSource
#1Yanting Zeng (Guangzhou Medical University)H-Index: 2
#2Jianan Li (ShanghaiTech University)H-Index: 8
Last. Xingxu Huang (CAS: Chinese Academy of Sciences)H-Index: 22
view all 10 authors...
There are urgent demands for efficient treatment of heritable genetic diseases. The base editing technology has displayed its efficiency and precision in base substitution in human embryos, providing a potential early-stage treatment for genetic diseases. Taking advantage of this technology, we corrected a Marfan syndrome pathogenic mutation, FBN1T7498C. We first tested the feasibility in mutant cells, then successfully achieved genetic correction in heterozygous human embryos. The results showe...
24 CitationsSource
#1Holly A. Rees (Broad Institute)H-Index: 10
#2David R. Liu (Broad Institute)H-Index: 73
RNA-guided programmable nucleases from CRISPR systems generate precise breaks in DNA or RNA at specified positions. In cells, this activity can lead to changes in DNA sequence or RNA transcript abundance. Base editing is a newer genome-editing approach that uses components from CRISPR systems together with other enzymes to directly install point mutations into cellular DNA or RNA without making double-stranded DNA breaks. DNA base editors comprise a catalytically disabled nuclease fused to a nuc...
75 CitationsSource
#1Xingliang Guo (SJTU: Shanghai Jiao Tong University)H-Index: 1
#2Hua Jiang (SJTU: Shanghai Jiao Tong University)H-Index: 13
Last. Zonghai Li (SJTU: Shanghai Jiao Tong University)H-Index: 16
view all 12 authors...
Cancer immunotherapy has made unprecedented breakthrough in the fields of chimeric antigen receptor-redirected T (CAR T) cell therapy and immune modulation. Combination of CAR modification and the disruption of endogenous inhibitory immune checkpoints on T cells represents a promising immunotherapeutic modality for cancer treatment. However, the potential for the treatment of hepatocellular carcinoma (HCC) has not been explored. In this study, the gene expressing the programmed death 1 receptor ...
10 CitationsSource
Cited By1
#1Waseem QasimH-Index: 28
The rapid evolution of tools for genome editing has created a dizzying array of possibilities for novel therapeutic strategies, even though to date only a handful of clinical applications have been realised. Proof-of-concept demonstrations of targeted genome modification in vitro and in small animal models of inherited single gene disorders have to be translated into effective therapies. Interest has naturally gravitated towards opportunities for collection, ex vivo modification and return of bl...